Introduction

37
Therapeutic proteins account for an increasingly large proportion of pharmaceutical drugs 38 in recent years. These proteins are normally administered by subcutaneous injection (1) . When a 39 high dose of therapeutic proteins is required, the protein solution must often be very highly 40 concentrated to reduce the injection volume for patient convenience. However, such a high 41 protein concentration frequently leads to high viscosity, posing considerable challenges for both 42 processing and injection (2-4). For example, subcutaneous injection is generally performed with 43 solutions under 50 cP to reduce the time required for injection (5). Therefore, maintaining a 44 solution viscosity below 50 cP is a primary goal when developing high concentration 45 formulations of therapeutic proteins. 46
The viscosity of a protein solution is caused by noncovalent protein-protein interactions 47 such as electrostatic attraction or repulsion, leading to the formation of a transient three-48 dimensional network of protein (6). There has been considerable effort directed toward lowering 49 the viscosity of concentrated protein solutions through the application of various solution 50 additives (7-11). Among them, inorganic salts (12, 13) and hydrophobic salts (5, 14) have been 51
shown to effectively reduce the viscosity of protein solutions. However, some of these salts have 52 adverse effects on proteins, leading to destabilization and consequent aggregate formation (15). 53
Thus, there is always a demand for effective formulation conditions that reduce the viscosity of a 54 solution without compromising protein stability. 55
We have developed the application of ArgHCl for suppressing aggregation and 56 adsorption of various proteins during heat treatment and oxidative refolding (16-22). These 57 effects have been ascribed, at least in part, to the interaction of aromatic groups on arginine with 58 the protein surface (23). We have shown that ArgHCl binds to aromatic amino acids in proteins 59 3 using a crystal structure (24) and increases the solubility of low molecular weight solutes 60 containing aromatic moieties, consistent with the above mechanism (25-29). ArgHCl does not 61 destabilize the protein structure but decreases the probability of aggregation (30-36). Based on 62 its effects on protein aggregation, ArgHCl might also reduce the viscosity of protein solutions by 63 suppressing transient protein-protein interactions, thus preventing the formation of a three-64 dimensional network. In this work, we examined the effect of various amino acids on the 65 viscosity of bovine and human serum albumin (BSA and HSA, respectively). HSA is a clinically 66 important supplement for the loss of body fluid. This is the first report describing the application 67 of amino acids for reducing the viscosity of HSA solutions. Ltd. (Osaka, Japan). All chemicals were of reagent grade and were used as received. 77
The sample solution was prepared as follows: Serum albumin was dissolved in deionized 78 water, and the pH of the protein solution was adjusted to the desired values with 0.5 M NaOH or 79
HCl. The additive solution was mixed with the serum albumin solution to achieve the 80 appropriate concentrations of protein and additive, and the pH was then readjusted. 
Results and Discussion
94
Examination of the solution conditions
95
The viscosity of a protein solution is due, at least in part, to protein-protein interactions 96 and is therefore expected to change with pH; this behavior is similar to protein solubility, which 97 also depends on solution pH. The viscosity of a 40 mg/ml BSA solution as a function of pH was 98 reported previously (37). The lowest viscosity was observed at around pH 4.8, near the isoelectric 99 point (pI) of BSA, which is in good agreement with our experimental value (data not shown). It 100 is clear that the viscosity is greater when BSA is positively charged at pH 4.0 and negatively 101 charged above pH 6.0, which suggests the involvement of charge-charge repulsive interactions in 102 network formation. Figure 1 shows that the viscosity of the BSA solution at pH 7.4 is a function 103 of the protein concentration up to 300 mg/ml. The solution viscosity remained nearly constant 104 below 150 mg/ml. Further increases in protein concentration resulted in an exponential increase 105 in viscosity to over 100 cP at 300 mg/ml. 106
In order to confirm the structural change by such high concentration, we measured FTIR 107 spectra of BSA as a function of protein concentration at pH 6.8, which is the pH value of BSA 108 solutions not adjusted, due to the avoidance of unnecessary factors (Fig. 2) . The amide I and 109 amide II regions from 1,700 to 1,500 cm -1 of the FTIR spectra were clearly observed with the 110 BSA concentration of 75-300 mg/ml, which reflects the second structure of protein. The maximal 111 intensity of the amide I region at 1651 cm -1 increased with increasing the protein concentration. 112
The normalized spectra of the amide I and amide II regions of BSA with the concentration of 75-113 300 mg/ml were identical (Fig. 2B) , indicating that the secondary structure of BSA retained 114 constant even in the presence of high protein concentration. 115
116
Effect of amino acids on the viscosity of BSA solutions 117 Because the viscosity of BSA solution was dependent on both pH and protein 118 concentration, we took these parameters into consideration when determining the solution 119 conditions for evaluating the effects of various additives. We chose a pH of 7.4 because it is 120 preferable for injectable solutions to be similar to physiological conditions. At this pH, a 275 121 mg/ml BSA solution showed a viscosity of ~50 cP (see Fig. 1 ). Any additives that lower the 122 viscosity below this value may be acceptable for pharmaceutical applications (e.g., subcutaneous 123 injection). Using a pH of 7.4 and a concentration of 275 mg/ml, we examined the effects of 124 additives on the viscosity of a BSA solution. 125 ArgHCl, and NaCl. The viscosity of BSA sharply decreased with increasing concentrations of 142 ArgHCl, LysHCl, and NaCl up to ~50 mM. Above 50 mM, the viscosity of BSA appeared to 143 reach a plateau and was nearly independent of the additives, with all additives leading to a 1.5-144 fold reduction in viscosity. FTIR spectra showed that the secondary structure of BSA was not 145 altered even in the presence of 200 mM ArgHCl, LysHCl, and NaCl (Fig. 5) . These data indicate 146 that BSA does not undergo structural changes during reduction of the solution viscosity. 147
148
Effect of amino acids on the viscosity of HSA solutions 149 Finally, we performed the same experiments with human serum albumin (HSA) which is 150 similar in the pI and the sequence to BSA, as it has commercial value as a formulation excipient 151 and plasma expander. Figure 6 shows the viscosity of 305 mg/ml HSA at pH 7.4 in the presence 152 of 200 mM amino acid or salt. A pattern similar to that observed for BSA was noted; the 153 viscosity of HSA was decreased 1.6-fold by ArgHCl and LysHCl, whereas the other amino acids 154 had marginal effects. As with BSA, NaCl and GdnHCl were as effective as, or slightly more 155 effective than, LysHCl and ArgHCl with respect to reducing the viscosity of the HSA solution. 156 157
Molecular mechanisms of viscosity reduction by ArgHCl and LysHCl
158
The pH dependence of BSA solution viscosity is intriguing. The viscosity was at a 159 minimum at approximately pH 4.8, which is near the pI of BSA (37). This result indicated that 160 the protein-protein interactions in relation to solution viscosity were also at a minimum. In other 161 words, the viscosity of BSA solutions significantly increased on both sides of the pI, meaning 162 that stronger protein-protein interactions that affect solution viscosity occur when BSA acquires 163 net charges, regardless of whether these charges are negative or positive. Although the 164 acquisition of net charges causes overall repulsion between protein molecules, either 165 deprotonation of carboxyl groups (below the pI) or protonation of His and Lys (above the pI) 166 may enhance the local electrostatic interaction between BSA molecules, leading to increased 167 formation of transient noncovalent networks and a consequent increase in solution viscosity. 168 We expected that protein solubility would be related to solution viscosity. Protein 169 solubility is normally minimal at the pI (38) . Near the pI, the net charge of a protein should be 170 close to zero, causing minimal charge repulsion and enhancing protein-protein interactions. 171
Protein-protein interactions that determine protein solubility may be related to the transient 172 8 formation of a protein network that increases solution viscosity. Thus, it was expected that the 173 viscosity of BSA solution would be maximal near its pI. However, the viscosity was at a 174 minimum near the pI of BSA (37). Electrostatic interactions are thought to be important in high 175 concentration formulations of monoclonal antibodies (13, 39). Thus, this unexpected result 176 indicated that the type of protein-protein interaction that plays a role in high viscosity is different 177 from the type of interaction responsible for determining protein solubility. 178
The effects of additives were examined at the physiological pH of 7.4. At this pH, BSA 179 has a net negative charge that apparently results in a greater viscosity than that which occurs at 180 the isoelectric pH of ~5 (37). The current study revealed that ArgHCl or LysHCl at 200 mM 181 significantly reduced the viscosities of both BSA and HSA solutions, although those of 50 mM 182 may be sufficient to achieve the same level of reduction (Fig. 4) 
